Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT06413537
PHASE2
Study of SPG601 in Adult Men With Fragile X Syndrome
Sponsor: Spinogenix
View on ClinicalTrials.gov
Summary
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.
Official title: A Phase 2a, Randomized, Double-Blinded, Study Evaluating the Neurophysiologic vs Clinical Effects of Single-Dose SPG601 and Placebo in Adult Men With Fragile X Syndrome
Key Details
Gender
MALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2024-07-05
Completion Date
2024-12-31
Last Updated
2026-05-26
Healthy Volunteers
No
Conditions
Interventions
DRUG
SPG601
synthetic small molecule
DRUG
Placebo
Placebo
Locations (1)
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States